Things are looking up for Alzheimer's researchers, who presented hard data in a recent issue of Nature that usage of Viagra, a drug that is commonly used to treat erectile dysfunction, is "significantly associated with a 69% reduced risk of Alzheimer's disease." — Read the rest

Posted in r/MadeMeSmile by u/nycsellit4me • 12,467 points and 233 comments

Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.

A new study links obesity with 21 Alzheimer's disease-related genes.

Biogen, Eisai Alzheimer's drug Leqembi covered by VA

Researchers from Karolinska Institutet have reported new insights on how copper ions inhibit the aggregation of the amyloid-ß peptide implicated in Alzheimer's disease. The study published in JACS Au presents molecular structures of this complex, which provide a general understanding of the impact metal ions have.

Brian Barbour has not been seen in three days and Vancouger police believe he may have trouble finding his way home due to his Alzheimer's.

(marketscreener.com) – Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer’s disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying Trappsol® Cyclo™ for the treatment of early Alzheimer’s diseasehttps//www.marketscreener.com/quote/stock/CYCLO-THERAPEUTICS-INC-11094839/news/Cyclo-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2b-Study-of-Trappsol-Cyclo-trade-for-the-42692355/?utm_medium=RSS&utm_content=20230109

Eisai exec expects full approval of Alzheimer's therapy Leqembi this summer - CNBC

(marketscreener.com) DEEP-LEARNING METHODS FOR ENRICHMENT OF ALZHEIMER'S DISEASE CLINICAL TRIALS USING MRI AND PET Luis R Peraza, Robin Wolz, Richard Joules IXICO plc, London, UK. ...https//www.marketscreener.com/quote/stock/IXICO-PLC-46321439/news/IXICO-Deep-learning-methods-for-enrichment-of-Alzheimer-s-Disease-clinical-trials-using-MRI-and-PE-43413823/?utm_medium=RSS&utm_content=20230403

Researchers have identified neurons in the brain that may contribute to some of the earliest symptoms of Alzheimer's disease, making it a good target for potential new drugs to treat the disease.

The American College of Surgeons (ACS) is the recipient of a $100,000 grant from the Council of Medical Specialty Societies (CMSS) to develop comprehensive educational resources to improve surgical care and outcomes for older adults with Alzheimer's disease and related dementias who are undergoing surgery.

(marketscreener.com) – Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer’s disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying Trappsol® Cyclo™ for the treatment of early Alzheimer’s diseasehttps//www.marketscreener.com/quote/stock/CYCLO-THERAPEUTICS-INC-11094839/news/Cyclo-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2b-Study-of-Trappsol-Cyclo-trade-for-the-42692355/?utm_medium=RSS&utm_content=20230109

Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts

(marketscreener.com) AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD AL044, a novel first-in-class therapeutic candidate, seeks to counteract multiple AD pathologies through modulating microglia, the brain’s immune cells Company has three novel immuno-neurology drug candidates in development to...https//www.marketscreener.com/quote/stock/ALECTOR-INC-54379343/news/Alector-Initiates-Phase-1-Clinical-Trial-of-AL044-for-the-Treatment-of-Alzheimer-s-Disease-AD-41750412/?utm_medium=RSS&utm_content=20220912

Cassava Appears Overvalued And Lacks Rigorous Alzheimer's Data

Clinicians say people with Alzheimer's could flock to a costly new drug made by Biogen. That could make it harder to develop better treatments.

A major week, for better or worse, for Alzheimer's drug development.

(marketscreener.com) BERWYN, Pa., Oct. 6, 2022 /PRNewswire/ -- Annovis Bio, Inc. , a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the U.S. Food and Drug Administration has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease . ...https//www.marketscreener.com/quote/stock/ANNOVIS-BIO-INC-102588345/news/Annovis-Bio-Announces-FDA-Authorization-to-Proceed-with-Phase-2-3-Trial-for-Buntanetap-in-Alzheimer-41941550/?utm_medium=RSS&utm_content=20221006

Even modest drinking can speed up the loss of brain cells and formation of the plaques that are a hallmark of Alzheimer's disease, research in mice shows.

(marketscreener.com) Company To Host Conference Call on Friday, December 2 at 11 a.m. EThttps//www.marketscreener.com/quote/stock/INDIA-GLOBALIZATION-CAPIT-57355601/news/IGC-Commences-Phase-2-Clinical-Trials-Evaluating-Drug-Candidate-IGC-AD1-for-the-Treatment-of-Agitati-42453715/?utm_medium=RSS&utm_content=20221201

Even modest drinking can speed up the loss of brain cells and formation of the plaques that are a hallmark of Alzheimer's disease, research in mice shows.

CRISPR gene editing could be used to introduce a rare gene variant that greatly reduces the risk of Alzheimer's, but it has only been tried in a dish so far

Former NFL head coach Marty Schottenheimer was moved to a hospice facility near his home in Charlotte, North Carolina, on Saturday due to complications from Alzheimer's Disease, his family said Wednesday.

(marketscreener.com) - - ...https//www.marketscreener.com/quote/stock/IXICO-PLC-46321439/news/IXICO-Application-of-fully-automatic-Hippocampal-sub-field-segmentation-volumes-to-standard-resolu-42527497/?utm_medium=RSS&utm_content=20221212

(marketscreener.com) Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022 -- Cassava Sciences, Inc. , a...https//www.marketscreener.com/quote/stock/CASSAVA-SCIENCES-INC-56537199/news/Cassava-Sciences-Announces-Completion-of-Dosing-in-Open-label-Study-of-Simufilam-for-Alzheimer-s-Dis-42486239/?utm_medium=RSS&utm_content=20221206

Cutting-edge AI technologies that can detect subtle changes in a person's voice may help doctors diagnose Alzheimer's disease and other cognitive impairments even before other symptoms begin.

Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.

Alzheimer's disease is among the top causes of death in the US, and the cost of caring for people with dementia is about $290 billion a year.

In 2021, the US approved the first drug designed to treat the cause of Alzheimer's, but the European Union rejected it. Whether the drug can actually treat the chief symptoms of the disease will be a point of contention in 2022

Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates

(marketscreener.com) sponsored Phase 2 extended clinical trial evaluating the safety, tolerability, and long-term efficacy of Bryostatin-1 for the treatment of advanced Alzheimer's disease .Dr. Alan Tuchman, Synaptogenix Chief Executive Officer, stated, "Senior management and our Board of Directors have concluded an exploratory review of our business operations. With...https//www.marketscreener.com/quote/stock/SYNAPTOGENIX-INC-120797989/news/Synaptogenix-Provides-Corporate-Update-and-Outlines-Potential-Business-Opportunities-43181210/?utm_medium=RSS&utm_content=20230307

COLORADO SPRINGS, Colo. (KRDO) -- Saturday morning is the annual Walk to End Alzheimer's event at Prospect Lake in Colorado Springs. The Alzheimer's Association Walk to End Alzheimer's is the world's largest fundraiser for Alzheimer's care, support and research. The Association's goal is to raise awareness and funds to help put a stop to Alzheimer's.The post Colorado Springs community comes together for the annual ‘Walk to End Alzheimer’s’ event appeared first on KRDO.

(marketscreener.com) - - ...https//www.marketscreener.com/quote/stock/IXICO-PLC-46321439/news/IXICO-Application-of-fully-automatic-Hippocampal-sub-field-segmentation-volumes-to-standard-resolu-42527497/?utm_medium=RSS&utm_content=20221212

US to create Alzheimer's research database in ~$300M project - report

Biogen's Alzheimer's drug approval could pave the way for major changes across the industry.

Brigham and Women's Hospital is conducting the first human trial of an Alzheimer's nasal vaccine meant to prevent or slow the disease's progression.

Two doses of an FDA-approved sleeping pill reduced levels of Alzheimer's proteins in a small study of healthy volunteers. The study hints at the potential of sleep medications to slow or stop the progression of Alzheimer's disease, although much more work needs to be done to confirm the viability of such an approach.

Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.

Lecanemab Alzheimer's Drug Can Slow Cognitive Decline As Per New Data

Tiny robots that can transport individual neurons and connect them to form active neural circuits could help us study brain disorders such as Alzheimer's disease

Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout of the treatment will take years.

A former Perth charity founder walks free after a jury took just 10 minutes to find her not guilty of stealing $120,000 from her late mother, who had Alzheimer's disease.

Protein plaques associated with Alzheimer's disease may build up in the brain if sleep is disrupted because this affects cells that normally destroy them, according to a study involving mouse immune cells

Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.

The American College of Surgeons (ACS) is the recipient of a $100,000 grant from the Council of Medical Specialty Societies (CMSS) to develop comprehensive educational resources to improve surgical care and outcomes for older adults with Alzheimer's disease and related dementias who are undergoing surgery.

A member of an FDA advisory committee said Wednesday he had resigned over the agency's approval of a new Alzheimer's drug.

A new study in Science Advances adds weight to a growing body of evidence that iron dysregulation may play an important role in Alzheimer's disease and therefore might provide a better target for treatments than amyloid beta plaques.

Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.